Beyond its debilitating pain, migraine is a staggering global health crisis, affecting 39 million Americans and ranking as the world’s second leading cause of years lived with disability.
Key Takeaways
- Globally, migraine is the second leading cause of years lived with disability (YLDs) worldwide, accounting for 45.1 million YLDs in 2019.
- In the United States, approximately 39 million people suffer from migraine, representing about 12% of the population.
- Lifetime prevalence of migraine is 14% in the general population, 18% in women, and 6% in men.
- Migraine attacks last 4-72 hours untreated in 90% of cases.
- Unilateral head pain occurs in 60% of migraine episodes, bilateral in 40%.
- Throbbing or pulsating pain quality is reported in 85% of migraineurs.
- Female sex hormones fluctuate, triggering 60% of migraines in women.
- Family history increases risk 3-4 fold; 50-60% heritability.
- Stress triggers 50-70% of attacks.
- Triptans abort 70% of moderate-severe attacks within 2 hours.
- Prophylactic topiramate reduces attacks by 50% in 50% of patients.
- Beta-blockers (propranolol) effective in 50-60% for prevention.
- Migraine causes $78 billion annual economic burden in US.
- Chronic migraine leads to 44 workdays lost per year per patient.
- 50% of migraineurs miss work/school due to attacks annually.
Migraine affects millions globally, causing severe disability, especially among women during peak working years.
Epidemiology
1Globally, migraine is the second leading cause of years lived with disability (YLDs) worldwide, accounting for 45.1 million YLDs in 2019.
Verified2In the United States, approximately 39 million people suffer from migraine, representing about 12% of the population.
Verified3Lifetime prevalence of migraine is 14% in the general population, 18% in women, and 6% in men.
Verified4Migraine prevalence peaks between ages 25-55 years, with 20-30% of women and 10-15% of men affected in this range.
Directional5In Europe, the 1-year prevalence of migraine is 14.7%, affecting 15% of women and 8% of men.
Single source6Children aged 7-11 years have a migraine prevalence of 7-11%, rising to 8-23% in adolescents.
Verified7Migraine with aura occurs in 25-30% of migraine sufferers, while migraine without aura affects 70-75%.
Verified8In low- and middle-income countries, migraine underdiagnosis rate is over 80%.
Verified9US annual migraine incidence is 2,440 per 100,000 person-years for women and 790 for men.
Directional10Globally, females are 3 times more likely to have migraine than males, with a ratio of 3:1.
Single source11Migraine prevalence in Latin America is 14.7%, similar to North America and Europe.
Verified12In Asia, migraine prevalence is lower at 9-10%, but underreporting is high.
Verified13Postmenopausal women see a 30-50% reduction in migraine frequency.
Verified14Migraine accounts for 1.3% of all primary care visits in the US.
Directional15In Australia, 16% of the population experiences migraine annually.
Single source16Migraine remission rate is 40% by age 70.
Verified17In the UK, 190,000 migraine-related GP consultations occur yearly.
Verified18Pediatric migraine prevalence is 7.7% globally.
Verified19Migraine is more prevalent in urban (16%) than rural (12%) areas in developing countries.
Directional20In Canada, 14% of adults report migraine diagnosis.
Single source21Globally, migraine YLDs increased 20% from 1990-2019.
Verified22In India, migraine prevalence is 14.1% in urban adults.
Verified23Migraine onset before age 10 in 10-20% of cases.
Verified24Remission rate in children 20-40% by adulthood.
Directional25In Africa, prevalence estimated at 10-15% with high underdiagnosis.
Single source26US emergency visits for migraine: 1.2 million annually.
Verified27Migraine without aura 1-year prevalence 11.7% globally.
Verified28Aura prevalence 28% among diagnosed migraineurs.
Verified29Chronic migraine (>15 days/month) in 1-2% population.
Directional30Episodic migraine (0-14 days/month) in 12-15%.
Single source31Pediatric chronic migraine 1.8% prevalence.
VerifiedEpidemiology Interpretation
When you stack the staggering global disability, the stark gender gap, and the vast ocean of silent suffering against its frequent dismissal as 'just a headache,' it becomes clear that migraine is a neurological tyrant whose widespread, debilitating reign we have catastrophically underestimated.
Impact
1Migraine causes $78 billion annual economic burden in US.
Verified2Chronic migraine leads to 44 workdays lost per year per patient.
Verified350% of migraineurs miss work/school due to attacks annually.
Verified4Quality of life (SF-36) scores 20-30% lower in migraineurs.
Directional5Depression prevalence 45% higher in migraine patients.
Single source6Suicide attempt risk 2.5 times higher in migraine with aura.
Verified7Stroke risk 2-fold in migraine with aura women under 45.
Verified8Annual direct healthcare costs $11 billion in US for migraine.
Verified9Indirect costs (lost productivity) $13 billion yearly in US.
Directional1025% of migraineurs have severe disability (MIDAS score >20).
Single source11Migraineurs 2x more likely to have anxiety disorders.
Verified12Global DALYs for migraine 16 million in 2019.
VerifiedImpact Interpretation
Migraine is a neurological wrecking ball that not only shatters individual lives with pain and disability but also delivers a staggering $78 billion annual gut punch to the US economy, proving it's far more than just a bad headache.
Risk Factors
1Female sex hormones fluctuate, triggering 60% of migraines in women.
Verified2Family history increases risk 3-4 fold; 50-60% heritability.
Verified3Stress triggers 50-70% of attacks.
Verified4Sleep disturbances (insufficient or excess) trigger 35-50% of migraines.
Directional5Skipping meals provokes 40-57% of attacks.
Single source6Alcohol (red wine) triggers 30-35%, caffeine withdrawal 15-20%.
Verified7Sensory stimuli (bright lights 80%, strong smells 50%) common triggers.
Verified8Obesity increases chronic migraine risk 5-fold.
Verified9Depression comorbidity raises risk 2-5 times.
Directional10Smoking doubles migraine risk in women.
Single source11Oral contraceptives increase risk 2-3 fold in susceptible women.
Verified12Weather changes (barometric pressure) trigger 30-50%.
Verified13High caffeine intake (>200mg/day) triggers 14%.
Verified14Low socioeconomic status correlates with 1.5-2x higher prevalence.
Directional15Head trauma history increases risk 2-fold.
Single source16Chronic medication overuse escalates episodic to chronic in 50%.
Verified17Menstrual migraine in 60% of women, pure in 14%.
Verified18Low magnesium levels trigger 50% in deficient.
Verified19Dehydration triggers 33% of attacks.
Directional20Chocolate triggers 20-30%.
Single source21Hormonal replacement therapy increases risk 1.5-fold.
Verified22Anxiety disorders precede migraine onset in 30%.
Verified23Neck pain chronicity triggers 25%.
Verified24Bright screens/fluorescent lights 52% trigger.
Directional25Processed meats (nitrates) trigger 15%.
Single source26Shift work disrupts sleep, triggering 40%.
Verified27Olfactory triggers cause attacks with smell sensitivity 45%.
Verified28Monosodium glutamate (MSG) triggers 10-20%.
Verified29Raynaud's phenomenon comorbidity 25%.
Directional30Epilepsy history increases risk 3-fold.
Single sourceRisk Factors Interpretation
Your brain's migraine system is a temperamental diva who demands perfect hormonal balance, impeccable sleep, zero stress, and a timely meal, while also holding a grudge against your family history, your wine, your weather, and your paycheck.
Symptoms
1Migraine attacks last 4-72 hours untreated in 90% of cases.
Verified2Unilateral head pain occurs in 60% of migraine episodes, bilateral in 40%.
Verified3Throbbing or pulsating pain quality is reported in 85% of migraineurs.
Verified4Photophobia accompanies 80-90% of migraine attacks.
Directional5Phonophobia is present in 77% of attacks, osmophobia in 25-40%.
Single source6Nausea occurs in 60-95% of migraine episodes, vomiting in 30-50%.
Verified7Aura symptoms last 5-60 minutes in 99% of cases with aura.
Verified8Visual aura (scintillations, zigzags) affects 90% of aura migraineurs.
Verified9Sensory aura (paresthesias) occurs in 30-40% of aura cases.
Directional10Prodrome symptoms (fatigue, mood changes) precede 60% of attacks by 24 hours.
Single source11Postdrome (migraine hangover) lasts 24-48 hours in 80% of sufferers.
Verified12Moderate to severe pain intensity (7-10/10) in 90% of untreated attacks.
Verified13Aggravation by routine physical activity in 90% of cases.
Verified14Neck pain accompanies 75% of migraine attacks.
Directional15Allodynia (cutaneous sensitivity) during attacks in 70% of chronic migraineurs.
Single source16Vertigo in 30-50% of migraineurs, known as vestibular migraine.
Verified17Aura can include speech disturbances (aphasia) in 10-20%.
Verified18Basilar-type aura (dizziness, ataxia) rare at <1% of auras.
Verified19Facial sweating and nasal congestion in 20% during attacks.
Directional20Pain worsens with movement in 89% of attacks.
Single source21Blurred vision or blind spots in 25% aura cases.
Verified22Diarrhea or constipation in prodrome 20%.
Verified23Yawning excessively precedes 45% of attacks.
Verified24Food cravings (sweet/salty) in 30-50% prodrome.
Directional25Stiffness in neck/shoulders during 67% attacks.
Single source26Dizziness/vertigo in 40% of attacks without aura.
Verified27Hemiplegic migraine rare, <0.01% prevalence.
Verified28Olfactory hallucinations (auras) in 10%.
Verified29Cognitive fog during postdrome in 70%.
Directional3090% of untreated attacks last 24+ hours.
Single source31Aura motor weakness in hemiplegic 100% by definition.
Verified32Hyperacusis in 70-80% during attacks.
Verified33Fluid retention precedes 40% menstrual migraines.
Verified34Scalp tenderness in 60% post-attack.
DirectionalSymptoms Interpretation
Migraine is less a headache and more a meticulously cruel, hours-long theatrical production featuring throbbing spotlights, nausea as a supporting actor, a 24-hour sensory hangover, and the persistent stage direction that any attempt at normal movement will worsen your review.
Treatments
1Triptans abort 70% of moderate-severe attacks within 2 hours.
Verified2Prophylactic topiramate reduces attacks by 50% in 50% of patients.
Verified3Beta-blockers (propranolol) effective in 50-60% for prevention.
Verified4Botox injections reduce chronic migraine days by 8.4 per month.
Directional5CGRP monoclonal antibodies (erenumab) cut attacks by 50% in 50%.
Single source6NSAIDs (ibuprofen 400mg) relieve 50% of mild-moderate attacks.
Verified7Rimegepant (oral gepant) pain freedom at 2h in 21% vs 11% placebo.
Verified8Occipital nerve blocks provide relief in 70-80% for short-term.
Verified9Cognitive behavioral therapy reduces attack frequency by 30-50%.
Directional10Acupuncture decreases attacks by 50% in 53% of patients.
Single source11Magnesium supplementation (600mg/day) prevents in 41% deficient patients.
Verified12Feverfew herb reduces frequency by 24% over placebo.
Verified13Neuromodulation devices (Cefaly) reduce days by 50% in 30%.
Verified14Lasmiditan (5HT1F agonist) pain-free at 2h in 32% vs 15%.
Directional15Verapamil effective for cluster but 40% for migraine prevention.
Single source16Sumatriptan nasal spray 65% pain relief at 2h.
Verified17Amitriptyline prophylaxis reduces attacks 50% in 60%.
Verified18Candesartan as effective as beta-blockers, 50% response.
Verified19Ubrogepant pain freedom 22% at 2h vs 14% placebo.
Directional20OnabotulinumtoxinA (Botox) 50% responder rate 47%.
Single source21Ibuprofen + caffeine combo 55% effective vs 40% alone.
Verified22Yoga reduces frequency by 40% over 3 months.
Verified23Coenzyme Q10 (100mg tid) 50% reduction in 48%.
Verified24Petasites (butterbur) 68% response vs 45% placebo.
Directional25GammaCore vagus nerve stimulator 40% pain reduction.
Single source26Fremanezumab reduces monthly days by 7.6.
Verified27Galcanezumab 50% responder 62% vs 39% placebo.
Verified28Aspirin 900mg relieves 45% mild attacks.
Verified29Venlafaxine 150mg prevents 50% in 55%.
Directional30Nerivio device (remote electrical) 66% pain relief.
Single source31Eptinezumab IV reduces days by 8.5 monthly.
Verified32Atogepant oral CGRP reduces mMIDAS by 4.1.
Verified33Biofeedback success in 70% for prevention.
VerifiedTreatments Interpretation
Migraine treatment is a numbers game where we throw a lot of promising darts, but the board seems to have only three spaces: "works great for about half," "helps some of the people some of the time," or "hey, at least it's better than a sugar pill."
Sources & References
- Reference 1THELANCETthelancet.comVisit source
- Reference 2AMERICANMIGRAINEFOUNDATIONamericanmigrainefoundation.orgVisit source
- Reference 3PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 4CDCcdc.govVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6WHOwho.intVisit source
- Reference 7ICHD-3ichd-3.orgVisit source
- Reference 8NICEnice.org.ukVisit source
- Reference 9CANADAcanada.caVisit source
- Reference 10NEJMnejm.orgVisit source